Theratechnologies said it will ask Health Canada next year to approve donidalorsen, an experimental injection therapy designed to…
Articles by Marisa Wexler, MS
Astria Therapeutics is planning the launch of a Phase 3 clinical trial in early 2025 to test different dosing…
DRI Healthcare Trust, an investment firm, has acquired rights to royalty interest in sebetralstat, an on-demand treatment for…
Most people with hereditary angioedema (HAE) who received treatment with a 50 mg dose of the gene-editing therapy…
The case of an elderly man who developed acquired angioedema associated with an underlying blood disorder called monoclonal gammopathy…
An algorithm that takes into account factors such as the frequency and location of swelling attacks may help distinguish chronic…
Regulatory authorities in Japan, the U.S., and the European Union have aligned on plans for a Phase 3 clinical trial…
Authorities in the European Union (EU) have agreed to review Kalvista Pharmaceuticals’ application requesting the approval of oral…
Astria Therapeutics is teaming up with Ypsomed, a Swiss-based company, to develop an autoinjector for its experimental treatment…
A single dose of the gene-editing therapy NTLA-2002 led to significant reductions in the number of swelling attacks among…